Crinetics Pharmaceuticals: Citizens JMP Sees an Addressable Market of over $3 Billion in FDA Approval of Palsonify!

Crinetics Pharmaceuticals Inc. (CRNX) is currently gaining attention due to the approval of its main drug Palsonify (Paltusotine) by the U.S. Food and Drug Administration (FDA). This approval was granted on September 25, 2025, marking a significant milestone for the company. Palsonify is the first and only oral medication to be taken once daily for the treatment of acromegaly in adults who have not responded to surgery or for whom surgery is not an option. The drug's market launch is expected in early October 2025, significantly increasing expectations...